Search - tctmd.com

Displaying 861 - 880 of 1300

Sort: Relevancy | Date

News Daily News

PARADOX Publicado: La Paradoja del Fumador se observa con el Clopidogrel pero No con el Prasugrel

Caitlin E. Cox

May 13, 2013

Presentation

PARADOX: Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel

Presenter: Paul A. Gurbel

May 03, 2013

News Daily News

Los GPI son Superiores al Tratamientos de Rescate tras una Embolización Endovascular con Espirales contra Aneurismas Cerebrales

Caitlin E. Cox

May 03, 2013

News Daily News

La ESC Ofrece Recomendaciones para el Uso de Nuevos Anticoagulantes Orales

Yael L. Maxwell

May 03, 2013

News Daily News

GPIs Superior for Rescue Treatment after Endovascular Coiling for Cerebral Aneurysm

Caitlin E. Cox

May 03, 2013

News Daily News

ESC Offers Recommendations on Use of New Oral Anticoagulants

Yael L. Maxwell

May 03, 2013

News Daily News

La Bivalirudina Mejora a la Heprina en la Reducción del Riesgo Hemorrágico tras la CAS

L.A. McKeown

April 26, 2013

News Daily News

La Alta Reactividad Plaquetaria se asocia a Más Episodios Adversos tras Intervenciones Endovasculares

Yael L. Maxwell

April 26, 2013

News Daily News

High Platelet Reactivity Linked to More Adverse Events After Endovascular Procedures

Yael L. Maxwell

April 26, 2013

Presentation

Clinical Outcome Following Discontinuation of DAPT After 12 months in Real-World Patients Treated with Second-Generation ZES and EES

Presenter: K. Tandjung

April 26, 2013

News Daily News

Bivalirudin Bests Heparin for Lowering Bleeding Risk After CAS

L.A. McKeown

April 26, 2013

Presentation

Platelet Responsiveness to Clopidogrel Treatment After Peripheral Endovascular Procedures

Presenter: Stavros Spiliopoulos

April 25, 2013

Presentation TCTAP 2013

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Presenter: Matthew J. Price

April 24, 2013

Presentation TCTAP 2013

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

Presenter: Adnan Kastrati

April 24, 2013

News Daily News

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Caitlin E. Cox

April 19, 2013

News Daily News

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Caitlin E. Cox

April 19, 2013

Presentation

Hemorrhagic and Ischemic Outcomes After Bivalirudin vs. Heparin During CAS

Presenter: Siddharth A. Wayangankar

April 19, 2013

Presentation Fellows 2013

Platelet Function Testing, Genomics, and Antiplatelet Agent Resistance

Presenter: Matthew Price

April 16, 2013

Presentation Fellows 2013

Antiplatelet Therapy for the Interventionalist

Presenter: Matthew Price

April 16, 2013

Presentation

Decision Dilemmas in Adjunctive Pharmacology Choices in PCI Patients

Presenter: Roxana Mehran

April 15, 2013

Advertisement

PARADOX Publicado: La Paradoja del Fumador se observa con el Clopidogrel pero No con el Prasugrel

PARADOX: Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel

Los GPI son Superiores al Tratamientos de Rescate tras una Embolización Endovascular con Espirales contra Aneurismas Cerebrales

La ESC Ofrece Recomendaciones para el Uso de Nuevos Anticoagulantes Orales

GPIs Superior for Rescue Treatment after Endovascular Coiling for Cerebral Aneurysm

ESC Offers Recommendations on Use of New Oral Anticoagulants

La Bivalirudina Mejora a la Heprina en la Reducción del Riesgo Hemorrágico tras la CAS

La Alta Reactividad Plaquetaria se asocia a Más Episodios Adversos tras Intervenciones Endovasculares

High Platelet Reactivity Linked to More Adverse Events After Endovascular Procedures

Clinical Outcome Following Discontinuation of DAPT After 12 months in Real-World Patients Treated with Second-Generation ZES and EES

Bivalirudin Bests Heparin for Lowering Bleeding Risk After CAS

Platelet Responsiveness to Clopidogrel Treatment After Peripheral Endovascular Procedures

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Hemorrhagic and Ischemic Outcomes After Bivalirudin vs. Heparin During CAS

Platelet Function Testing, Genomics, and Antiplatelet Agent Resistance

Antiplatelet Therapy for the Interventionalist

Decision Dilemmas in Adjunctive Pharmacology Choices in PCI Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content